利马卡林 | 132014-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 中文名称: 利马卡林
• 英文名称: rilmakalim
• 英文别名: (3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxo-1-pyrrolidinyl)-6-phenylsulfonylchromane；1-[(3S,4R)-6-(benzenesulfonyl)-3-hydroxy-2,2-dimethyl-3,4-dihydrochromen-4-yl]pyrrolidin-2-one
• CAS: 132014-21-2
• 化学式: C₂₁H₂₃NO₅S
• 分子量: 401.483
• InChiKey: LKAQWOWWTKFLNX-UXHICEINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  92.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4-Dihydro-2,2-dimethyl-6-phenylsulfonyl-trans-4-(2-oxo1-pyrrolidinyl)-2H-benzo[b]pyran-3-ol 生成 利马卡林
  参考文献：
  名称：

  ENGLERT, HEINRICH-CHRISTIAN;KLAUS, ERIK;MANIA, DIETER;SCHOLKENS, BERNWARD

  摘要：

  DOI：

文献信息

• [EN] LACTONE INTERMEDIATES OF NICOTINAMIDE RIBOSIDE AND NICOTINATE RIBOSIDE<br/>[FR] INTERMÉDIAIRES DE LACTONE DE NICOTINAMIDE RIBOSIDE ET DE NICOTINATE RIBOSIDE
  申请人：UNIV BELFAST

  公开号：WO2018033639A1

  公开（公告）日：2018-02-22

  The present invention is directed to lactones of the following structural formula for use as precursors of NAD, and their use as nutritional supplements.

  本发明涉及以下结构式的内酯，用作NAD的前体，并且它们的用途作为营养补充剂。
• [EN] PREPARATION AND USE OF CRYSTALLINE BETA-D-NICOTINAMIDE RIBOSIDE<br/>[FR] PRÉPARATION ET UTILISATION DE BÊTA-D-NICOTINAMIDE RIBOSIDE CRISTALLIN
  申请人：GLAXOSMITHKLINE IP NO 2 LTD

  公开号：WO2015186068A1

  公开（公告）日：2015-12-10

  Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicotinamide riboside chloride compositions may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, or for increasing insulin sensitivity in a subject.

  本文提供晶体质的β-D-烟酰胺核苷酸氯化物组合物的制备和使用方法。还提供相关的药物组合物及其使用方法。晶体质的β-D-烟酰胺核苷酸氯化物组合物可用于治疗需要提高NAD水平的疾病或疾病，包括线粒体疾病或疾病，胰岛素抵抗，代谢综合征，糖尿病，肥胖症或用于增加受试者胰岛素敏感性。
• Use of a combination of active substances containing bioquinones for the production of cosmetic or dermatological preparations
  申请人：——

  公开号：US20030180278A1

  公开（公告）日：2003-09-25

  The invention relates to the use of a compound or several compounds from the group of bioquinones a) in combination with a compound or several compounds from the group of potassium channel openers and/or b) in combination with a compound or several compounds from the group of 5-alpha-reductase inhibitors, for the production of cosmetic or dermatological preparations for treatment of the scalp and for hair in order to prolong the anagenic phase and/or for the treatment and prophylaxis of seborrhoeic symptoms, optionally by additionally using one or several compounds from the group formed from carnitine, arginine, succinic acid, folic acid, conjugated fatty acids and respectively the derivatives thereof, in addition to antioxidants.

  本发明涉及使用生物喹诺酮类化合物或多个该类化合物a）与开放钾通道剂类化合物或多个该类化合物b）与5α-还原酶抑制剂类化合物或多个该类化合物组合，用于制备用于头皮治疗和头发的化妆品或皮肤科制剂，以延长毛发生长期和/或治疗和预防皮脂溢症状，可选择性地另外使用肉碱、精氨酸、琥珀酸、叶酸、共轭脂肪酸及其衍生物中的一个或多个化合物，以及抗氧化剂。
• Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
  申请人：——

  公开号：US20020045656A1

  公开（公告）日：2002-04-18

  This invention relates to methods of treating traumatic brain injury (TBI) or hypoxic or ischemic stroke, comprising administering to a patient in need of such treatment an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist in combination with either: (a) a neutrophil inhibitory factor (NIF); (b) a sodium channel antagonist; (c) a nitric oxide synthase (NOS) inhibitor; (d) a glycine site antagonist; (e) a potassium channel opener; (f) an AMPA/kainate receptor antagonist; (g) a calcium channel antagonist; (h) a GABA-A receptor modulator (e.g., a GABA-A receptor agonist); or (i) an antiinflammatory agent.

  本发明涉及治疗创伤性脑损伤（TBI）或缺氧性或缺血性中风的方法，包括向需要此类治疗的患者注射NR2B亚型选择性N-甲基-D-天门冬氨酸（NMDA）受体拮抗剂，与以下任一组合：（a）中性粒细胞抑制因子（NIF）；（b）钠通道拮抗剂；（c）一氧化氮合酶（NOS）抑制剂；（d）甘氨酸位点拮抗剂；（e）钾通道开放剂；（f）AMPA / kainate受体拮抗剂；（g）钙通道拮抗剂；（h）GABA-A受体调节剂（例如，GABA-A受体激动剂）；或（i）抗炎药物。
• Substituted benzenesulfonylureas and -thioureas-processes for their preparation and their use as pharmaceuticals
  申请人：Hoechst Aktiengesellschaft

  公开号：US20020058838A1

  公开（公告）日：2002-05-16

  Benzenesulfonylureas and -thioureas of the formula I 1 where R(1) is H or (fluoro)methyl, R(2) is H, Hal or (fluoro) (mercapto)alk(oxy)yl, E is O or S; Y is —[CR(3) 2 ] n —, where R(3)=H or alkyl and n=1-4, X is H, Hal or alkyl and Z is Hal, NO 3 or alk(yl)oxy, are described. The compounds I are used for treatment of disturbances in cardiac rhythm and prevention of sudden cardiac death caused by arrhythmia, and can therefore be used an antiarrhythmics. They are particularly suitable for those cases where arrhythmias are a consequence of a narrowing of a coronary vessel, such as angina pectoris or acute cardiac infarction.

  本文描述了式I1中的苯磺酰脲和-硫脲，其中R（1）为H或（氟）甲基，R（2）为H，卤素或（氟）（巯基）烷氧基，E为O或S；Y为- [CR（3）2] n-，其中R（3）= H或烷基，n = 1-4，X为H，卤素或烷基，Z为卤素，NO3或烷氧基。化合物I用于治疗心律失常和预防由心律失常引起的突发心脏死亡，因此可用作抗心律失常药物。它们特别适用于那些心律失常是冠状血管狭窄的后果，如心绞痛或急性心肌梗塞的情况。